TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 avr. 2024 09h10 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 mars 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
11 mars 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06 mars 2024 16h15 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
20 févr. 2024 08h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 janv. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
29 janv. 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
22 janv. 2024 16h45 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics closes public offering
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
18 janv. 2024 13h27 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering